Panacea Biotec Ltd banner

Panacea Biotec Ltd
NSE:PANACEABIO

Watchlist Manager
Panacea Biotec Ltd Logo
Panacea Biotec Ltd
NSE:PANACEABIO
Watchlist
Price: 329.9 INR 0.47% Market Closed
Market Cap: ₹20.2B

Wall Street
Price Targets

PANACEABIO Price Targets Summary
Panacea Biotec Ltd

There are no price targets for PANACEABIO.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Panacea Biotec Ltd Competitors:
Price Targets
PRQR
ProQR Therapeutics NV
496% Upside
NSIT
Insight Enterprises Inc
75% Upside
RCKT
Rocket Pharmaceuticals Inc
90% Upside
DXPE
DXP Enterprises Inc
-6% Downside
MASI
Masimo Corp
1% Upside

Revenue
Forecast

-2% / Year
Past Growth
2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
-2% / Year
Past Growth
2% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

For the last 13 years the compound annual growth rate for Panacea Biotec Ltd's revenue is -2%. The projected CAGR for the next 13 years is 2%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PANACEABIO's stock price target?
Not Available

PANACEABIO doesn't have any price targets made by Wall Street professionals.

What is Panacea Biotec Ltd's Revenue forecast?
Projected CAGR
2%

For the last 13 years the compound annual growth rate for Panacea Biotec Ltd's revenue is -2%. The projected CAGR for the next 13 years is 2%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett